Laennec injection solution 112mg / ml, 2ml No. 10

The drug is used in the complex therapy of the following diseases:

• chronic recurrent herpes

• moderate and severe atopic dermatitis (including complicated).

As monotherapy for chronic liver diseases: steatohepatitis (alcoholic metabolic and mixed etiology).

For chronic recurrent herpes and atopic dermatitis :

- intravenous drip: 10 ml (540 mg of placenta hydrolyzate) of the drug (5 ampoules) is dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the cubital vein for 15-2 hours. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment is 10 injections.

For chronic liver diseases : steatohepatitis (alcoholic metabolic and mixed etiology):

- intramuscularly: 2 ml per day (112 mg of placenta hydrolyzate). Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (up to 6 ml) per day;

- intravenous drip: 10 ml (560 mg of placenta hydrolyzate) of the drug (5 ampoules) is dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the cubital vein for 15-2 hours. Injections are given daily. The course of treatment is 2-3 weeks.

2 ml of the drug contains:

112 mg of human placenta hydrolyzate, water for injection, pH corrector (sodium hydroxide or hydrochloric acid).

• Hypersensitivity

• childhood

• pregnancy

• lactation period.

Carefully:

The drug should be used with caution in patients suffering from polyvalent allergy to drugs, as well as in the elderly.

Trade name of the drug

Laennec

Dosage form

injection

Composition

2 ml of the drug contains 112 mg of human placenta hydrolyzate, water for injection, pH corrector (sodium hydroxide or hydrochloric acid).

Description

Transparent liquid from light yellow to brown in color, with a characteristic odor.

Pharmacotherapeutic group

Hepatoprotective agent

Pharmacodynamics:

Laennec exhibits immunomodulatory properties due to the ability to stimulate humoral immunity and increase the functional activity of phagocytes and natural killer cells; increases the bactericidal activity of peripheral blood leukocytes, manifested in their ability to destroy the captured pathogen. The cytokines in the preparation activate the metabolic and supervisory functions of skin cells. Biologically active substances in the hydrolyzate stimulate the regeneration (proliferation) of hepatocytes; exhibit detoxification properties; reduce the deposition of lipids and cholesterol in hepatic cells; increase the activity of tissue respiration; activate metabolism in the liver; reduce the intensity of development of connective tissue in the liver.

Indications:

The drug is used in the complex therapy of the following diseases:

• chronic recurrent herpes

• moderate and severe atopic dermatitis (including complicated).

As monotherapy for chronic liver diseases: steatohepatitis (alcoholic metabolic and mixed etiology).

Contraindications:

• Hypersensitivity

• childhood

• pregnancy

• lactation period.

Carefully:

The drug should be used with caution in patients suffering from polyvalent allergy to drugs, as well as in the elderly.

Pregnancy and lactation:

The use of the drug during pregnancy and breastfeeding is contraindicated.

Method of administration and dosage:

For chronic recurrent herpes and atopic dermatitis :

- intravenous drip: 10 ml (540 mg of placenta hydrolyzate) of the drug (5 ampoules) is dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the cubital vein for 15-2 hours. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment is 10 injections.

For chronic liver diseases : steatohepatitis (alcoholic metabolic and mixed etiology):

- intramuscularly: 2 ml per day (112 mg of placenta hydrolyzate). Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (up to 6 ml) per day;

- intravenous drip: 10 ml (560 mg of placenta hydrolyzate) of the drug (5 ampoules) is dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the cubital vein for 15-2 hours. Injections are given daily. The course of treatment is 2-3 weeks.

Side effects:

It is noted in 37% of patients.

Clinically significant adverse reactions

Allergic reactions are possible, including anaphylactic shock.

Other adverse events

Soreness at the injection site - 256%

Allergic reactions (redness, itching of the skin) - 037%

Numbness at the injection site - 037%

Gynecomastia (a causal relationship with the administration of the drug has not been established - 037%

Overdose:

Currently, no cases of Laennec overdose have been reported.

Interaction:

When Laennec is mixed with other drugs that are strong bases (pH above 85), as a result of pharmaceutical interaction, its activity decreases.

To date, there are no data on any other clinically significant interactions of Laennec.

Special instructions:

Use of the drug in children

Studies on the safety of Laennec's use in premature infants, infants and minors have not been conducted. The use in children is not recommended.

The use of the drug in the elderly

According to the currently available data, advanced age is not a contraindication for the appointment of Laennec. However, since physiological functions in the elderly are impaired, the use of the drug should be carefully monitored.

Impact on the ability to drive vehicles. Wed and fur .:

The effect on the ability to drive vehicles with mechanisms has not been established.

Release form / dosage:

Injection.

Packaging:

2 ml in amber ampoules of hydrolytic class 2; each ampoule has a white spot indicating the place where the ampoule was broken.

10 or 50 ampoules in a cardboard box with cardboard partitions with instructions for use.

Hospital packaging: 200 ampoules in a cardboard box with cardboard partitions with instructions for use.

Storage conditions:

At a temperature of 18 to 25 ? C in a dark place.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date indicated on the package.

Vacation conditions

On prescription.